RV

Revvity IncNYSE RVTY Stock Report

Last reporting period 29 Sep, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

15.069

Large

Exchange

XNYS - New York Stock Exchange, Inc

RVTY Stock Analysis

RV

Neutral

Based on Eyestock quantitative analysis, RVTY`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

55/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-63.3 %

Overvalued

Market cap $B

15.069

Dividend yield

0.29 %

Shares outstanding

123.39 B

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. The company is headquartered in Waltham, Massachusetts and currently employs 11,500 full-time employees. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. The company offers instruments, reagents, assay platforms and software to hospitals, and medical labs. The company is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.

View Section: Eyestock Rating